0 674

Cited 17 times in

The prognostic role of tertiary Gleason pattern 5 in a contemporary grading system for prostate cancer

DC Field Value Language
dc.contributor.author강동혁-
dc.contributor.author강용진-
dc.contributor.author김명수-
dc.contributor.author윤철용-
dc.contributor.author정원식-
dc.contributor.author최영득-
dc.contributor.author함원식-
dc.date.accessioned2017-11-02T08:35:14Z-
dc.date.available2017-11-02T08:35:14Z-
dc.date.issued2017-
dc.identifier.issn1365-7852-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154643-
dc.description.abstractBACKGROUND: Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the prognostic role of TGP5 in the new classification. METHODS: We retrospectively reviewed the records of 1396 patients with localized GS 6-8 PC (pT2-3N0M0) who underwent radical prostatectomy at our institution between 2005 and 2014. After excluding patients who received neoadjuvant or adjuvant therapy, or had incomplete pathological or follow-up data, 1229 patients were included in the final analysis. The Kaplan-Meier method was used to estimate and compare the probabilities of biochemical recurrence (BCR). Cox regression models were used to investigate associations between variables and the risk of BCR. RESULTS: Of 732 GS 7 patients, 75 (10.2%) had a TGP5. The BCR-free survival rate for men with TGP5 was significantly worse than for those without TGP5 (P<0.001). In multivariate Cox regression analyses for GS 7 PC, TGP5 was a significant predictor of BCR (hazard ratio 1.750, P=0.027). When the total cohort was stratified into four grade groups according to the new classification, group 2 with TGP5 had a BCR risk comparable to group 3, and group 3 with TGP5 behaved like group 4. CONCLUSIONS: Our study shows that TGP5 increased the BCR risk after RP in GS 7 PC. Moreover, we demonstrated that the presence of a TGP5 in GS 7 upgraded the BCR risk to one comparable with the next higher category under the new classification. These findings support incorporating TGP5 into GS 7 to aid with future risk assessment and follow-up scheduling for PC.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherNature Publishing Group-
dc.relation.isPartOfPROSTATE CANCER AND PROSTATIC DISEASES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Grading-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHProstatic Neoplasms/mortality*-
dc.subject.MESHProstatic Neoplasms/pathology*-
dc.subject.MESHProstatic Neoplasms/therapy-
dc.subject.MESHRecurrence-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTumor Burden-
dc.titleThe prognostic role of tertiary Gleason pattern 5 in a contemporary grading system for prostate cancer-
dc.typeArticle-
dc.publisher.locationEngland-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Urology-
dc.contributor.googleauthorW S Jang-
dc.contributor.googleauthorC Y Yoon-
dc.contributor.googleauthorM S Kim-
dc.contributor.googleauthorD H Kang-
dc.contributor.googleauthorY J Kang-
dc.contributor.googleauthorW S Jeong-
dc.contributor.googleauthorM J Abalajon-
dc.contributor.googleauthorW S Ham-
dc.contributor.googleauthorY D Choi-
dc.identifier.doi10.1038/pcan.2016.55-
dc.contributor.localIdA04711-
dc.contributor.localIdA05091-
dc.contributor.localIdA04988-
dc.contributor.localIdA05180-
dc.contributor.localIdA04111-
dc.contributor.localIdA04337-
dc.contributor.localIdA04870-
dc.contributor.localIdA05268-
dc.relation.journalcodeJ02558-
dc.identifier.eissn1476-5608-
dc.identifier.pmid27845330-
dc.identifier.urlhttp://www.nature.com/pcan/journal/v20/n1/full/pcan201655a.html?foxtrotcallback=true-
dc.contributor.alternativeNameKang, Dong Hyuk-
dc.contributor.alternativeNameKang, Yong Jin-
dc.contributor.alternativeNameKim, Myung Soo-
dc.contributor.alternativeNameYoon, Cheol Yong-
dc.contributor.alternativeNameJeong, Won Sik-
dc.contributor.alternativeNameChoi, Young Deuk-
dc.contributor.alternativeNameHam, Won Sik-
dc.contributor.affiliatedAuthorKang, Yong Jin-
dc.contributor.affiliatedAuthorKim, Myung Soo-
dc.contributor.affiliatedAuthorYoon, Cheol Yong-
dc.contributor.affiliatedAuthorJeong, Won Sik-
dc.contributor.affiliatedAuthorChoi, Young Deuk-
dc.contributor.affiliatedAuthorHam, Won Sik-
dc.contributor.affiliatedAuthorKang, Dong Hyuk-
dc.citation.titleProstate Cancer and Prostatic Diseases-
dc.citation.volume20-
dc.citation.number1-
dc.citation.startPage93-
dc.citation.endPage98-
dc.identifier.bibliographicCitationPROSTATE CANCER AND PROSTATIC DISEASES, Vol.20(1) : 93-98, 2017-
dc.date.modified2017-11-01-
dc.identifier.rimsid43701-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.